The Carlyle Group and GTCR LLC are poised to complete the takeover of Albany Molecular Research (AMRI) after the early termination of the mandatory waiting period that covers such deals in the US.
Symbiosis has opened an office in Boston, Massachusetts citing growing demand for vial filling services for highly potent APIs and large molecule injectable formulations.
Plans to centralise its manufacturing operations will optimise use of new technologies across Novartis’s divisions without resulting in any additional facility closures, the firm says.
Unilife has invested in manufacturing capacity for its drug delivery devices ahead of schedule to support the accelerated commercial launch date of its customers' products.
M+W says a lack of synergies with its engineering and construction business drove the decision to sell its automation divison to ATS for €255m ($348m).
Sun Pharmaceutical Industries has abandoned its long running efforts to buy Israel’s Taro, explaining the move is in the best interest of shareholders.
Submitting a REMS (Risk Evaluation and Mitigation Strategies) proposal for risky drug developments could earn companies brownie points, according to Quintiles’ Ed Tabor.
APP Pharmaceuticals has bought additional facilities at a site in Grand Island, New York seizing the opportunity created by Astellas Manufacturing’s decision to shift production of its dermatitis drug Protopic to Japan.
Pall Life Sciences gave Outsourcing-Pharma.com an update on its
budding operations in India, one of the most promising markets for
the firm, where the pharmaceutical industry is growing at a rate of
nearly 9 per cent annually.
Predictions that the generics industry will experience further
consolidation - made at the annual meeting of the International
Generic Pharmaceutical Alliance this week - have been swiftly
followed by the news that Sandoz is buying...
Japan's Taiyo Pharmaceutical Industry is planning to increase its
contract manufacturing operations in the wake of new government
legislation that makes it easier for firms to produce drugs for
third parties.
